Welcome
Support Centre
01 November 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ ...Back to search results ] [ Print-friendly version ]
Primary prevention of gestational diabetes among women at risk: a cluster-randomized controlled trial
ISRCTN ISRCTN33885819
DOI 10.1186/ISRCTN33885819
ClinicalTrials.gov identifier
EudraCT number
Public title Primary prevention of gestational diabetes among women at risk: a cluster-randomized controlled trial
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Women at risk (overweight, age 40 years or older, earlier macrosomic child, diabetic first stage relatives) will receive intensified diet and physical activity counselling, which prevents their gestational diabetes.
Lay summary Not provided at time of registration
Ethics approval Ethical Committee of Pirkanmaa Hospital District. Approved on 24/02/2007. Amendments approved on 11/09/2007 (ref: R02630)
Study design A cluster-randomized controlled trial.
Countries of recruitment Finland
Disease/condition/study domain Gestational diabetes
Participants - inclusion criteria Pregnant women in their 8-12th pregnancy week and with at least one of the following criteria:
1. Body mass index at least 25 kg/m2
2. Age at least 40 years
3. History of gestational diabetes or macrosomic child
4. Type 1 or 2 diabetes in any of the first stage relatives
Participants - exclusion criteria 1. Age < 18 years
2. Type 1 or 2 diabetes before pregnancy
3. Twin pregnancy or otherwise problematic pregnancy based on physician's opinion
4. Physical disability preventing from exercising
5. Substance abuse or history of severe mental illness
Anticipated start date 15/09/2007
Anticipated end date 31/12/2008
Status of trial Completed
Patient information material
Target number of participants 600
Interventions 14 counties are participating in the trial. They are randomised to the intervention and control groups (7 counties each).

Intervention group: Intensified, tailored diet and physical activity counselling during five scheduled visits to a public health nurse in maternity health care. Visits take place at 8-9, 16-18, 22-24, 32-34 and 36-37 pregnancy weeks. In addition to physical activity counselling, participants have monthly meetings with peers guided by a physiotherapist.

Participants in the maternity health care in control counties receive usual care only.

(See ISRCTN21512277 for pilot study)
Primary outcome measure(s) Prevention of gestational diabetes, assessed by:
1. Oral glucose tolerance test during pregnancy weeks 26-28
2. Weight of the newborn
Secondary outcome measure(s) 1. Maternal weight development. Maternal weight will be measured 5 times during pregnancy, on pregnancy weeks 8-9, 16-18, 22-24, 32-34 and 36-37, and 6-8 weeks after delivery.
2. Child weight development, followed one year after delivery.
3. Need of insulin treatment during pregnancy. This will be determined at time of possible GDM diagnosis (earliest 26-28th week of pregnancy based on Oral Glucose Tolerance Test [OGTT]).
Sources of funding 1. National Institutes of Health (USA)
2. Ministries of Education and Social Affairs and Health (Finland)
3. Diabetes Research Fund (Finland)
4. Pirkanmaa Hospital District (EVO) (Finland)
Trial website
Publications 1. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20682023
2. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21610860
3. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22950716
4. 2013 cost-effectiveness in http://www.ncbi.nlm.nih.gov/pubmed/23457562
Contact name Dr  Riitta  Luoto
  Address UKK Institute
post box 30
33501
  City/town Tampere
  Zip/Postcode 33501
  Country Finland
  Email riitta.luoto@uta.fi
Sponsor The Urho Kaleva Kekkonen (UKK) Institute for Health Promotion Research (Finland)
  Address Post box 30
  City/town Tampere
  Zip/Postcode 33501
  Country Finland
  Email uktutkimus@uta.fi
  Sponsor website: http://www.ukkinstituutti.fi/en/
Date applied 12/09/2007
Last edited 06/03/2013
Date ISRCTN assigned 03/10/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.